港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

勁方醫藥-B

28.020

-1.740-5.85%

成交量：104.16萬

成交額：2,988.49萬

市值：103.67億

市盈率：-14.18

高：31.180

開：30.360

低：27.540

收：29.760

52周最高：50.200

52周最低：24.320

股本：3.70億

香港流通股本：3.38億

量比：0.71

換手率：0.31%

股息：- -

股息率：- -

每股收益(LYR):-1.976

淨資產收益率：--

總資產收益率：-30.27%

市淨率：-3.60

市盈率(LYR):-14.18

市銷率: 49.10

資料載入中...

總覽公司新聞公告

勁方醫藥-B10月23日主力淨流入174.2萬元散户資金拋售

港股異動 | 勁方醫藥-B(02595)由跌轉漲逾9% GFH375聯合療法治療晚期實體瘤研究完成首例入組

智通财经网

勁方醫藥-B(02595)：KRAS G12D抑制劑GFH375聯合西妥昔單抗或化療治療晚期實體瘤的Ib/II期研究完成首例患者給藥

勁方醫藥-B(02595)10月21日因超額配股權獲行使而發行1338.6萬股

勁方醫藥-B10月21日遭主力拋售81.9萬元

刷新港股18A紀錄！國產RAS創新藥龍頭勁方醫藥即將敲鐘

勁方醫藥-B10月20日遭主力拋售284.6萬元

勁方醫藥-B(02595)：悉數行使超額配股權、穩定價格期結束

多隻醫藥新股上市頭日收漲超100%！包括曾申報科創板IPO未果的新股

勁方醫藥GFH375片啓動Ib/II期臨牀適應症為晚期實體瘤

勁方醫藥-B10月10日遭主力拋售118.2萬元

【IPO追蹤】充電樁賽道龍頭來了！摯達科技首日暴漲超180%

勁方醫藥-B10月09日主力淨流出863.7萬元散户資金買入

「全球新」推動「全球化」！從「藥谷首家」到「數量翻倍」，浦東生物醫藥迎來「上市潮」

勁方醫藥-B10月02日獲主力加倉622.1萬元

勁方醫藥-B：2025 年中期報告

香港交易所

浦東生物醫藥企業競逐「全球新」

勁方醫藥-B(02595)分子膠Pan RAS(ON)抑制劑GFH276治療RAS突變型癌症患者的I/II期臨牀試驗首位患者完成入組

國信證券-醫藥生物行業週報（25年第36周）：勁方醫藥在港交所上市

勁方醫藥-B09月25日主力淨流出839.0萬元散户資金買入

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/02595/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"勁方醫藥-B","latestPrice":28.02,"timestamp":1761293120109,"preClose":29.76,"halted":0,"volume":1041600,"delay":0,"floatShares":338000000,"shares":370000000,"eps":-1.976,"marketStatus":"未開盤","change":-1.74,"latestTime":"10-24 16:05:20","open":30.36,"high":31.18,"low":27.54,"amount":29884900,"amplitude":0.122312,"askPrice":28,"askSize":13800,"bidPrice":27.98,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.744,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1761528600000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":29.76,"openAndCloseTimeList":[[1761269400000,1761278400000],[1761282000000,1761292800000]],"volumeRatio":0.706046950538445,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-30.27%","roe":"--","lyrEps":-1.976,"volumeRatio":0.706046950538445,"shares":370000000,"dividePrice":0,"high":31.18,"amplitude":0.122312,"preClose":29.76,"low":27.54,"week52Low":24.32,"pbRate":"-3.60","psRate":"49.10","week52High":50.2,"institutionHeld":0,"latestPrice":28.02,"committee":-0.971429,"eps":-1.976,"divideRate":0,"volume":1041600,"delay":0,"ttmEps":-2.744,"open":30.36,"prevYearClose":20.39,"prevWeekClose":28.02,"prevMonthClose":40,"prevQuarterClose":40,"fiveDayClose":31.8,"twentyDayClose":40.64,"sixtyDayClose":20.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2025-10-24","current":-10.21137,"percent":0.956522,"low":-19.62221,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"high":-9.058573,"avg":-14.513639,"sd":4.050774,"marketCap":9676444452},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452}],"updateTime":1761495137035},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577584296","title":"勁方醫藥-B10月23日主力淨流入174.2萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2577584296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577584296?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 16:15","pubTimestamp":1761207342,"startTime":"0","endTime":"0","summary":"10月23日, 劲方医药-B股价涨12.22%，报收29.76元，成交金额5535.3万元，换手率0.62%，振幅25.19%，量比1.33。劲方医药-B今日主力资金净流入174.2万元，上一交易日主力净流出114.1万元。该股近5个交易日下跌3.85%，主力资金累计净流出541.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1242.8万元，其中净流出天数为12日。该股主力净额占比0.02%，港股市场排名271/2682。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161930a47030d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023161930a47030d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","02595","BK1515","BK1574"],"gpt_icon":0},{"id":"2577789573","title":"港股異動 | 勁方醫藥-B(02595)由跌轉漲逾9% GFH375聯合療法治療晚期實體瘤研究完成首例入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2577789573","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577789573?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 15:17","pubTimestamp":1761203842,"startTime":"0","endTime":"0","summary":"消息面上，劲方医药宣布，旗下口服高活性及高选择性小分子KRAS G12D抑制剂GFH375，联合疗法用于治疗KRAS G12D突变型晚期实体瘤的Ib/II期研究，首例患者已在北京大学肿瘤医院完成入组。该项研究今年9月获得国家药监局临床试验批准，涉及联合西妥昔单抗或化疗两项联合疗法，其中GFH375联合化疗方案为一线胰腺导管腺癌治疗方案。报告聚焦该试验600 mgQD剂量组PDAC患者的研究数据，显示GFH375治疗PDAC患者的疗效突出且安全性可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358628.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1515","159938","09939","BK1161","02595"],"gpt_icon":0},{"id":"2577198386","title":"勁方醫藥-B(02595)：KRAS G12D抑制劑GFH375聯合西妥昔單抗或化療治療晚期實體瘤的Ib/II期研究完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2577198386","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577198386?lang=zh_tw&edition=fundamental","pubTime":"2025-10-22 07:34","pubTimestamp":1761089667,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375联合疗法治疗KRAS G12D突变型晚期实体瘤的Ib/II期研究首例患者在北京大学肿瘤医院完成入组。Ib期试验将首先在北京大学肿瘤医院等约15家中心开展，整体试验的主要研究目的为评估GFH375联合西妥昔单抗或化疗两项联合疗法在实体瘤患者中的安全性╱耐受性、疗效和药代动力学特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","09939","BK1161","02595","BK1515"],"gpt_icon":1},{"id":"2577847319","title":"勁方醫藥-B(02595)10月21日因超額配股權獲行使而發行1338.6萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577847319","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577847319?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 16:33","pubTimestamp":1761035615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2025年10月21日因超额配股权获悉数行使而发行及配发1338.6万股H股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1574","02595","159938","BK1161"],"gpt_icon":0},{"id":"2577353888","title":"勁方醫藥-B10月21日遭主力拋售81.9萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577353888","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577353888?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 16:16","pubTimestamp":1761034569,"startTime":"0","endTime":"0","summary":"10月21日, 劲方医药-B股价跌6.37%，报收29.38元，成交金额3006.1万元，换手率0.30%，振幅9.31%，量比0.73。劲方医药-B今日主力资金净流出81.9万元，连续6日净流出，上一交易日主力净流出284.6万元。该股近5个交易日下跌5.09%，主力资金累计净流出882.8万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2700.0万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021162256a6c57539&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021162256a6c57539&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09939","BK1515","02595"],"gpt_icon":0},{"id":"2577358057","title":"刷新港股18A紀錄！國產RAS創新藥龍頭勁方醫藥即將敲鐘","url":"https://stock-news.laohu8.com/highlight/detail?id=2577358057","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577358057?lang=zh_tw&edition=fundamental","pubTime":"2025-10-21 15:48","pubTimestamp":1761032919,"startTime":"0","endTime":"0","summary":"基石投资者认购总额已达1亿美元，也创2022年以来港股 18A 生物科技公司新高。氟泽雷塞于2024年8月上市，为中国首个、全球第三个获批上市的KRAS G12C抑制剂。NSCLC、CRC、PDAC发病人数持续攀升。作为全球首个KRAS+EGFR一线肺癌联合疗法，其总体疗效优秀，且具有显著的脑转移肿瘤缓解、优于氟泽雷塞二线单药治疗的安全性。此外，GFH375有望与劲方的泛RAS抑制剂、EGFR-Pan RAS偶联药物，以及恶病质双抗GFS202A在未来形成狙击胰腺癌的疗法矩阵。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021161810a6c572b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251021161810a6c572b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02595","BK1515","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2576863005","title":"勁方醫藥-B10月20日遭主力拋售284.6萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576863005","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576863005?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 16:15","pubTimestamp":1760948154,"startTime":"0","endTime":"0","summary":"10月20日, 劲方医药-B股价跌1.32%，报收31.38元，成交金额3853.4万元，换手率0.37%，振幅6.10%，量比0.92。劲方医药-B今日主力资金净流出284.6万元，连续5日净流出，上一交易日主力净流出234.7万元。该股近5个交易日下跌8.63%，主力资金累计净流出906.5万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出2618.1万元，其中净流出天数为12日。该股主力净额占比0.03%，港股市场排名2542/2681。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020162043a6c3533f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020162043a6c3533f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","02595","BK1515","BK1161"],"gpt_icon":0},{"id":"2575674517","title":"勁方醫藥-B(02595)：悉數行使超額配股權、穩定價格期結束","url":"https://stock-news.laohu8.com/highlight/detail?id=2575674517","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575674517?lang=zh_tw&edition=fundamental","pubTime":"2025-10-16 20:05","pubTimestamp":1760616345,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，独家保荐人兼整体协调人(为其本身及代表国际包销商)已于2025年10月16日悉数行使招股章程所述的超额配股权，涉及合共1338.6万股H股，占于任何超额配股权获行使前全球发售项下可供认购发售股份总数约15%(经计及发售量调整权获悉数行使)。超额配发股份将由公司按每股H股20.39港元发行及配发。超额配发股份将用于补足国际发售的超额分配。 此外，有关全球发售的稳定价格期已于2025年10月16日(即递交香港公开发售申请截止日期后第30日)结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1574","BK1161","159938","02595","BK1515"],"gpt_icon":0},{"id":"2575530714","title":"多隻醫藥新股上市頭日收漲超100%！包括曾申報科創板IPO未果的新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575530714","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575530714?lang=zh_tw&edition=fundamental","pubTime":"2025-10-16 16:58","pubTimestamp":1760605089,"startTime":"0","endTime":"0","summary":"银诺医药的暴涨更凸显了市场对核心创新资产的追捧。中国已成为全球第二大医药市场，其中创新药领域增长尤为迅猛。医药研发具有周期长、投入大、风险高的特点，一款新药从临床前研究到上市平均需投入 10 亿美元以上，成功率不足 10%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016170328a462f942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016170328a462f942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","BK1161","00460","02575","BK1515","09939","BK1574"],"gpt_icon":1},{"id":"2574517334","title":"勁方醫藥GFH375片啓動Ib/II期臨牀 適應症為晚期實體瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2574517334","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574517334?lang=zh_tw&edition=fundamental","pubTime":"2025-10-11 18:03","pubTimestamp":1760176980,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，劲方医药科技（上海）有限公司的一项多中心、开放标签，探索GFH375联合西妥昔单抗或AG在实体瘤参与者中的安全性/耐受性、PK特征，探索联合用药疗效的Ib/II期临床研究已启动。该药物剂型为片剂，规格为100mg/片，用法为口服，按方案规定使用。GFH375片为化学药物，适应症为晚期实体瘤。晚期实体瘤指癌细胞已扩散至身体其他部位的肿瘤，症状因肿瘤类型而异，常见有疼痛、消瘦等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101119070594c3121b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101119070594c3121b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02595","09939","BK1161","BK1515"],"gpt_icon":1},{"id":"2574487483","title":"勁方醫藥-B10月10日遭主力拋售118.2萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574487483","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574487483?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 16:15","pubTimestamp":1760084149,"startTime":"0","endTime":"0","summary":"10月10日, 劲方医药-B股价跌4.42%，报收34.60元，成交金额4217.3万元，换手率0.37%，振幅11.44%，量比1.21。劲方医药-B今日主力资金净流出118.2万元，上一交易日主力净流出863.7万元。该股近5个交易日下跌17.46%，主力资金累计净流出117.7万元；近20日主力资金累计净流出1941.5万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101016210697264c5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101016210697264c5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","02595","BK1161"],"gpt_icon":0},{"id":"2574410021","title":"【IPO追蹤】充電樁賽道龍頭來了！摯達科技首日暴漲超180%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574410021","media":"IPO解码","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574410021?lang=zh_tw&edition=fundamental","pubTime":"2025-10-10 14:05","pubTimestamp":1760076309,"startTime":"0","endTime":"0","summary":"而在10月10日，又有金叶国际集团、挚达科技两只新股同时上市，且都在首日迎来暴涨。其中，挚达科技出现高开大涨，截至发稿时间已飙升超180%，市值超过了110亿港元整数关口。此外，国际配售方面，挚达科技获2.37倍认购，国际发售股份最终数目为538.10万股股份，相当于发售股份总数的90%。根据弗若斯特沙利文的资料，2022年至2024年及2025年前三个月，按家用电动汽车充电桩销量计，挚达科技的中国市场份额达13.6%，全球市场份额达到9.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010140948a6b2a6fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010140948a6b2a6fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","02583","02595","02650"],"gpt_icon":1},{"id":"2574016660","title":"勁方醫藥-B10月09日主力淨流出863.7萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574016660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574016660?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 16:15","pubTimestamp":1759997734,"startTime":"0","endTime":"0","summary":"10月09日, 劲方医药-B股价跌8.22%，报收36.20元，成交金额7915.2万元，换手率0.65%，振幅9.43%，量比2.84。劲方医药-B今日主力资金净流出863.7万元，上一交易日主力净流入129.7万元。该股近5个交易日下跌9.45%，主力资金累计净流入622.6万元；近20日主力资金累计净流出1823.3万元，其中净流出天数为6日。该股主力净额占比0.07%，港股市场排名2539/2673。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091621099724e17d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510091621099724e17d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","02595","BK1161"],"gpt_icon":0},{"id":"2574661153","title":"「全球新」推動「全球化」！從「藥谷首家」到「數量翻倍」，浦東生物醫藥迎來「上市潮」","url":"https://stock-news.laohu8.com/highlight/detail?id=2574661153","media":"浦东发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574661153?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 09:45","pubTimestamp":1759974355,"startTime":"0","endTime":"0","summary":"从2018年君实生物成为“张江药谷”首家港股18A上市企业后，浦东生物医药企业赴港上市“热潮”汹涌，“厚积薄发”的浦东生物医药产业正迎来从“量变”走向“质变”，成为“价值金矿”。“全球新”推动“全球化”“差异化”获得市场高估值我国创新药虽然高速发展，但一些领域也存在跟随创新多、同质化严重、临床价值优势不明显等问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009103408a6b155d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009103408a6b155d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02595","01877","BK1583","BK1574","09939","BK1515","06978","BK1161"],"gpt_icon":0},{"id":"2572957691","title":"勁方醫藥-B10月02日獲主力加倉622.1萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572957691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572957691?lang=zh_tw&edition=fundamental","pubTime":"2025-10-02 16:15","pubTimestamp":1759392932,"startTime":"0","endTime":"0","summary":"10月02日, 劲方医药-B股价涨4.80%，报收41.92元，成交金额5112.2万元，换手率0.38%，振幅5.75%，量比0.62。劲方医药-B今日主力资金净流入622.1万元，上一交易日主力净流入38.9万元。该股近5个交易日上涨3.15%，主力资金累计净流出816.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出1823.8万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100216174194b84857&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025100216174194b84857&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","BK1161","02595"],"gpt_icon":0},{"id":"2571411443","title":"勁方醫藥-B：2025 年中期報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2571411443","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571411443?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 18:42","pubTimestamp":1759228931,"startTime":"0","endTime":"0","summary":"牛牛AI助手已提取核心信息劲方医药科技(上海)股份有限公司公布2025年中期业绩。劲方医药科技(上海)股份有限公司公布2025年中期业绩。研发成本为1.2244亿元人民币，较去年同期1.86亿元下降34.2%，主要由于去年同期产生终止中国境外选择权及专利许可协议费用。公司核心产品GFH925(达伯特)已于2024年8月获国家药监局批准上市，成为中国首款及全球第三款获批的KRAS抑制剂。另一核心产品GFH375正在中国进行I/II期临床试验，并已于2025年2月启动II期部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191626971a3cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191626971a3cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02595","BK1574","09939","BK1161"],"gpt_icon":1},{"id":"2571134119","title":"浦東生物醫藥企業競逐「全球新」","url":"https://stock-news.laohu8.com/highlight/detail?id=2571134119","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571134119?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 18:22","pubTimestamp":1759227774,"startTime":"0","endTime":"0","summary":"今年以来，浦东生物医药企业资本市场表现活跃：劲方医药、银诺医药已赴港上市，多家企业密集递交申请。自2018年君实生物成为张江药谷首家港股18A上市企业后，浦东药企赴港上市热潮涌动，产业正从“量变”迈向“质变”。出海方面，今年上半年浦东生物医药企业出海交易近30起，交易额占全国31%、全球14%。据悉，浦东将在2025上海国际生物医药产业周期间，围绕“源头创新 链聚全球”推出更多服务与政策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01877","02591","02595","BK1161","09939","BK1515"],"gpt_icon":1},{"id":"2571299335","title":"勁方醫藥-B(02595)分子膠Pan RAS(ON)抑制劑GFH276治療RAS突變型癌症患者的I/II期臨牀試驗首位患者完成入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2571299335","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571299335?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 20:40","pubTimestamp":1759149659,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH276治疗RAS突变型晚期实体瘤的I/II期试验首例患者近日已完成入组。目前全球尚无泛RAS靶向药获批上市，GFH276开发进度位于Pan RAS抑制剂赛道的全球前三位。GFH276临床研究的Ia期临床试验将在中山大学肿瘤防治中心、上海复旦大学附属肿瘤医院等约10家研究中心开展。GFH276可靶向抑制多数活化状态的野生╱突变型RAS蛋白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ199S13.USD","LU0124384867.USD","LU0724618433.USD","LU1720051017.SGD","LU1861215975.USD","BK4605","LU1854104046.USD","LU1861214812.USD","BK4141","LU1854103824.USD","LU2357305700.SGD","LU1720051108.HKD","159938","BK4512","ON","02595","BK4585","LU1548497426.USD","LU1978683503.SGD","IE00BD6J9T35.USD","BK1515","LU2360107325.USD","LU2298322129.HKD","BK4588","LU1861220033.SGD","LU0348723411.USD","LU1861219969.SGD","BK1574","BK1161","09939"],"gpt_icon":1},{"id":"2570016202","title":"國信證券-醫藥生物行業週報（25年第36周）：勁方醫藥在港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2570016202","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570016202?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 22:37","pubTimestamp":1758811036,"startTime":"0","endTime":"0","summary":"劲方医药专注RAS相关靶向分子研发，成功在港交所主板上市。劲方医药成立于2017年8月，2025年9月19日在港交所主板上市。公司具有全球视野、全球运营及国内外合作，并已有首款创新药获批上市，聚焦肿瘤、自免和炎症疾病领域研发创新有效的治疗方案。核心产品GFH925与合作伙伴信达生物共同推进研发及商业化，并于2024年8月在国内获批上市，用于治疗2线及以上的KRASG12C突变的NSCLC，成为国内首款、全球第三款获批的KRASG12C选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092522394797a97de1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092522394797a97de1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","BK1161","02595"],"gpt_icon":1},{"id":"2570062064","title":"勁方醫藥-B09月25日主力淨流出839.0萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2570062064","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570062064?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 16:16","pubTimestamp":1758788167,"startTime":"0","endTime":"0","summary":"09月25日, 劲方医药-B股价跌1.53%，报收40.02元，成交金额1.0亿元，换手率0.78%，振幅6.64%，量比0.00。劲方医药-B今日主力资金净流出839.0万元，上一交易日主力净流入389.6万元。该股近5个交易日上涨96.17%，主力资金累计净流出1846.6万元；近20日主力资金累计净流出1846.6万元，其中净流出天数为3日。该股主力净额占比0.06%，港股市场排名2553/2671。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162846a69d2fa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925162846a69d2fa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02595","BK1515","BK1161","09939"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}]}}